MaaT Pharma announces the successful completion of its Global Offering of 19.2 Million Euros

Regulatory News:


THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR...

Related Keywords

United Kingdom ,Japan ,United States ,Canada ,France ,French ,Karim Dabbagh ,Bpifrance Investissement ,Financial Services ,Company Board Of Directors On ,European Parliament ,French Financial Markets Authority Autorit ,Regulatory News ,Microbiome Ecosystem ,Primary Offering ,Seventure Partners ,Offering Price ,Reserved Offering ,Maat Pharma ,Global Offering ,French Commercial Code ,French Monetary ,Financial Code ,Selling Shareholder ,Euronext Paris ,Chief Executive Officer ,Ordinary Shares ,Existing Share Capital ,Enlarged Share Capital ,Mutuel Innovation ,Jean Marie Lef ,Placement Agents ,Global Coordinator ,Joint Bookrunner ,Gilbert Dupont ,Groupe Soci ,Primarybid Offering ,French Financial Markets Authority ,Des March ,Prospectus Regulation ,Microbiome Ecosystem Therapies ,Member States ,European Economic Area ,Member State ,Markets Act ,Financial Promotion ,Market Act ,Relevant Person ,Securities Act ,